|
Ocugen Inc
OCGN's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Looking into Ocugen Inc growth rates, revenue grew
in II. Quarter 2024 from the same quarter a year ago.
Ranking at No. 304
Biotechnology & Pharmaceuticals industry recorded
growth of revenues by 12.58 %
Ocugen Inc net loss decreased from $-23 millions, to $-5 millions in II. Quarter 2024,
• More on OCGN's Growth
|
|
Ocugen Inc realized a net loss in trailing twelve months.
Ocugen Inc realized cash reduction of $ -0.1 per share in trailing twelve-month period. Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 30.11.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.85.
• More on OCGN's Valuation
|
|
|
|
|
Ocugen Inc realized net loss in trailing twelve months.
Ocugen Inc realized cash outflow of $ -0.1per share in trailing twelve-month period. Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 30.11.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.85.
Ocugen Inc Price to Book Ratio is at 14.57 lower than Industry Avg. of 1041.5. and higher than S&P 500 Avg. of 0
• More on OCGN's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2024 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com